finance.yahoo.com ·
eli lilly lly reports q1 045705034
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEli Lilly's strong Q1 results and raised guidance reflect surging demand for GLP-1 metabolic drugs (Mounjaro, Zepbound) and pipeline progress. The commercial mechanism is demand_spike for incretin-based therapies, expanding Lilly's revenue and margins. Impact is company-specific (Eli Lilly) and sector-wide (GLP-1 class).
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Eli Lilly Q1 2026 revenue $19.8B, +56% YoY
- Mounjaro revenue $8.7B, Zepbound $4.1B
- GAAP EPS $8.26, +170% YoY
- FDA approved Foundayo (GLP-1 pill)
- FY2026 guidance raised to $82-85B
Obesity drug adoption may drive healthcare spending, but prescription growth is gradual.
Sign in to see all sector verdicts, full thesis and counter-argument debate.